Prediction of New-Onset Diabetes Mellitus within 12 Months after Liver Transplantation—A Machine Learning Approach

Background: Liver transplantation (LT) is a routine therapeutic approach for patients with acute liver failure, end-stage liver disease and/or early-stage liver cancer. While 5-year survival rates have increased to over 80%, long-term outcomes are critically influenced by extrahepatic sequelae of LT and immunosuppressive therapy, including diabetes mellitus (DM). In this study, we used machine learning (ML) to predict the probability of new-onset DM following LT. Methods: A cohort of 216 LT patients was identified from the Disease Analyzer (DA) database (IQVIA) between 2005 and 2020. Three ML models comprising random forest (RF), logistic regression (LR), and eXtreme Gradient Boosting (XGBoost) were tested as predictors of new-onset DM within 12 months after LT. Results: 18 out of 216 LT patients (8.3%) were diagnosed with DM within 12 months after the index date. The performance of the RF model in predicting the development of DM was the highest (accuracy = 79.5%, AUC 77.5%). It correctly identified 75.0% of the DM patients and 80.0% of the non-DM patients in the testing dataset. In terms of predictive variables, patients’ age, frequency and time of proton pump inhibitor prescription as well as prescriptions of analgesics, immunosuppressants, vitamin D, and two antibiotic drugs (broad spectrum penicillins, fluocinolone) were identified. Conclusions: Pending external validation, our data suggest that ML models can be used to predict the occurrence of new-onset DM following LT. Such tools could help to identify LT patients at risk of unfavorable outcomes and to implement respective clinical strategies of prevention.

[1]  Zhen Zhang,et al.  Progress of new-onset diabetes after liver and kidney transplantation , 2023, Frontiers in Endocrinology.

[2]  J. Tanner,et al.  Effects of Intensive Blood Glucose Control on Surgical Site Infection for Liver Transplant Recipients: A Randomized Controlled Trial. , 2022, Transplantation proceedings.

[3]  N. Syn,et al.  A Meta‐Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  L. Rostaing,et al.  Adverse effects of immunosuppression after liver transplantation. , 2021, Best practice & research. Clinical gastroenterology.

[5]  M. Woo,et al.  Metabolic Complications in Liver Transplantation Recipients: How We Can Optimize Long‐Term Survival , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  L. Nguyen,et al.  Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies , 2020, Gut.

[7]  Anna Goldenberg,et al.  Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review , 2020, Hepatology.

[8]  E. Gorokhova,et al.  Disparate effects of antibiotic-induced microbiome change and enhanced fitness in Daphnia magna , 2019, bioRxiv.

[9]  K. Watt,et al.  New‐Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long‐Term Survival After Liver Transplant: A Machine Learning Approach , 2018, Mayo Clinic proceedings.

[10]  W. Rathmann,et al.  Basic characteristics and representativeness of the German Disease Analyzer database
. , 2018, International journal of clinical pharmacology and therapeutics.

[11]  Peer Bork,et al.  Extensive impact of non-antibiotic drugs on human gut bacteria , 2018, Nature.

[12]  Lanjuan Li,et al.  The Origin of New-Onset Diabetes After Liver Transplantation: Liver, Islets, or Gut? , 2016, Transplantation.

[13]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[14]  Tim D Spector,et al.  Proton pump inhibitors alter the composition of the gut microbiota , 2015, Gut.

[15]  Jingyuan Fu,et al.  Proton pump inhibitors affect the gut microbiome , 2015, Gut.

[16]  T. M. A. Fernandez,et al.  Critical Care of the Liver Transplant Recipient , 2015, Current Anesthesiology Reports.

[17]  M. Senzolo,et al.  Perioperative thrombotic complications in liver transplantation. , 2015, World journal of gastroenterology.

[18]  B. Müllhaupt,et al.  Challenges to liver transplantation and strategies to improve outcomes. , 2015, Gastroenterology.

[19]  G. Dedemadi,et al.  Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review. , 2014, World journal of gastroenterology.

[20]  S. Mallett,et al.  Transfusion and coagulation management in liver transplantation. , 2014, World journal of gastroenterology.

[21]  Q. Xia,et al.  Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: A systematic review and meta‐analysis , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  H. Ohdan,et al.  Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. , 2014, Transplantation proceedings.

[23]  O. Dirsch,et al.  Liver transplantation and inflammation: is lipopolysaccharide binding protein the link? , 2013, Cytokine.

[24]  D. Slakey,et al.  Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. , 2013, Transplantation reviews.

[25]  Zhuye Jie,et al.  Human Gut Microbiota Changes Reveal the Progression of Glucose Intolerance , 2013, PloS one.

[26]  E. Porrini,et al.  The Higher Diabetogenic Risk of Tacrolimus Depends on Pre‐Existing Insulin Resistance. A Study in Obese and Lean Zucker Rats , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  K. Clément,et al.  Gut microbiota and non-alcoholic fatty liver disease: new insights. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  L. Mandarino,et al.  Calcineurin inhibition and new-onset diabetes mellitus after transplantation. , 2013, Transplantation.

[29]  B. Stecher,et al.  'Blooming' in the gut: how dysbiosis might contribute to pathogen evolution , 2013, Nature Reviews Microbiology.

[30]  Haiyang Xie,et al.  Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. , 2013, Journal of hepatology.

[31]  Qiang Feng,et al.  A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.

[32]  A. Burroughs,et al.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). , 2012, Journal of hepatology.

[33]  Shu-sen Zheng,et al.  Changes of gut bacteria and immune parameters in liver transplant recipients. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[34]  Ian R. Lanza,et al.  Unique Cellular and Mitochondrial Defects Mediate FK506-Induced Islet &bgr;-Cell Dysfunction , 2011, Transplantation.

[35]  J. Sonnenburg,et al.  Specificity of Polysaccharide Use in Intestinal Bacteroides Species Determines Diet-Induced Microbiota Alterations , 2010, Cell.

[36]  B. Müllhaupt,et al.  Current and future trends in liver transplantation in Europe. , 2010, Gastroenterology.

[37]  D. Samuel,et al.  Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[38]  William M. Lee,et al.  Acute liver failure: Summary of a workshop , 2007, Hepatology.

[39]  M. Márques,et al.  Tacrolimus‐Induced Diabetes in Rats Courses with Suppressed Insulin Gene Expression in Pancreatic Islets , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  K. Wernecke,et al.  Major influence of liver function itself but not of immunosuppression determines glucose tolerance after living‐donor liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[41]  J. Figueras,et al.  Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. , 2006, Journal of hepatology.

[42]  R. Fisher,et al.  Four‐year follow‐up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation , 2004, Clinical transplantation.

[43]  F. Cosio,et al.  Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. , 2002, Kidney international.

[44]  Lucila Ohno-Machado,et al.  Logistic regression and artificial neural network classification models: a methodology review , 2002, J. Biomed. Informatics.

[45]  Michael Keith Random Forest , 2021, Machine Learning with Regression in Python.

[46]  A. Burroughs,et al.  EASL Clinical Practice Guidelines: Liver transplantation. , 2016, Journal of hepatology.